DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Danaher - 2 Beckman Coulter - 2 Jim Cramer's - 2 Jim Cramer - 2 Jim - 2 Blair - 1 Igor Golovnov - 1 we've - 1
Top related locs:
China North America Europe bioprocessing Danaher Biotechnology Asia Pacific
Top related orgs:
LSEG - 2 Biotechnology - 2 Management - 2 CNBC - 2 Getty - 2 Bloomberg - 1 Revenue - 1 JPMorgan Healthcare - 1

Search resuls for: "Beckman Coulter"


2 mentions found


☆ Danaher shares jump 7% as the turnaround in biotech spending finally arrives
  + stars: | 2024-04-23 | by ( Zev Fima | ) www.cnbc.com   time to read: +8 min
Shares of Danaher popped more than 7% on Tuesday after the life sciences company delivered beats across its three main businesses — a sign the long-awaited turnaround in the biotech industry is finally here. Danaher Why we own it : Danaher is a best-in-class life sciences and diagnostics company, with a management team who have proven time and again their ability to find new ways to grow. The turnaround is now in effect, with bioprocessing orders up on a sequential basis. Within the segment, bioprocessing sales fell a "high teens" percentage, while discovery and medical declined 20% year over year. Diagnostics sales advanced 7.5% on a core basis to $2.53 billion.
Persons: Danaher, Blair, Beckman Coulter, Jim Cramer's, Jim Cramer, Jim, Igor Golovnov Organizations: LSEG, Bloomberg, Biotechnology, Management, CNBC, Getty Locations: bioprocessing, China, North America, Europe
☆ Danaher shares hit a 1-year high after earnings and we're increasing our price target
  + stars: | 2024-01-30 | by ( Zev Fima | ) www.cnbc.com   time to read: +10 min
DHR 1Y mountain Danaher 1 year Shares of Danaher rose as much as 5% to a 52-week high of $245.40 each. Core sales, not shown on the table, were down 22.5%. Core sales were down 4% year over year as strength from academic and life science research customers was more than offset by weakness from pharma and biopharma customers. Core sales fell about the same as strength in clinical diagnostics, driven by Beckman Coulter Diagnostics was more than offset by lower respiratory revenue at Cepheid. In this photo illustration, Danaher Corporation logo is seen displayed on a smartphone and PC screen.
Persons: we've, Danaher, Beckman Coulter, Jim Cramer's, Jim Cramer, Jim, Pavlo Gonchar Organizations: Revenue, LSEG, JPMorgan Healthcare, Sciences, Diagnostics, Biotechnology, Management, pharma, Beckman Coulter Diagnostics, CNBC, Getty Locations: Danaher, China, Biotechnology, North America, Europe, Asia, Pacific, Cepheid
0 next >>
Total: 2